Physician profile
Shivani Gupta
NPI 1467864389
$200,598.72
in general payments reported to CMS, 2019-2025
22 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $8,359 · 2022: $4,310 · 2023: $49K · 2024: $66K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $24K · Honoraria: $12K · Food and Beverage: $4,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $146,719.76 |
| Travel and Lodging | $24,060.48 |
| Honoraria | $12,100.00 |
| Food and Beverage | $4,866.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $193,320.47 | 2021-2025 | Dysport |
| Abbvie INC. | $3,334.92 | 2022-2024 | |
| Allergan, INC. | $1,833.64 | 2020-2021 | |
| Ipsen Pharma Sas | $840.89 | 2022 | |
| Merz Pharmaceuticals, LLC | $297.66 | 2024-2025 | Xeomin |
| Piramal Critical Care | $204.64 | 2021-2024 | |
| Medtronic, INC. | $185.96 | 2021-2024 | Synchromedii |
| Amgen INC. | $144.53 | 2020-2022 | |
| Medtronic USA, INC. | $95.93 | 2020 | |
| Biodelivery Sciences International, INC. | $55.63 | 2021 | |
| Supernus Pharmaceuticals, INC. | $41.97 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $35.01 | 2022 | |
| Eisai INC. | $34.83 | 2021-2022 | |
| Biogen, INC. | $33.42 | 2021 | |
| Ucb, INC. | $32.17 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $20.17 | 2025 | Daxxify |
| Mdd US Operations, LLC | $18.65 | 2022 | |
| Scilex Pharmaceuticals INC. | $16.12 | 2021 | |
| Lilly USA, LLC | $13.59 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.55 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.